Core Viewpoint - The article highlights the emergence of female fund managers in the pharmaceutical sector, particularly during the current innovative drug market boom, showcasing their impressive performance and unique investment strategies [3][6][18]. Group 1: Performance of Female Fund Managers - Zhang Wei, known as the "new pharmaceutical queen," leads the market with her fund, achieving a maximum return of 176.96% this year, with a current return of 142.74% as of October 13 [3][11]. - Other notable female fund managers, such as Ge Lan, Zhao Bei, and Tan Xiaobing, have also excelled, with their funds ranking high in performance, reflecting diverse investment philosophies in the innovative drug sector [5][18]. - The overall performance of these fund managers indicates a strong recovery in the innovative drug market after a prolonged downturn [7][18]. Group 2: Investment Strategies - Zhang Wei's investment strategy focuses on large-cap stocks in the pharmaceutical sector, with 90.83% of her portfolio allocated to pharmaceutical and biotechnology companies, reflecting a significant increase of 28.55% from the previous period [11][15]. - Ge Lan emphasizes cross-border collaborations and clinical expectations, actively participating in private placements to enhance risk-reward ratios [28][29]. - Zhao Bei adopts a more conservative approach, diversifying her portfolio to include both innovative and traditional pharmaceutical companies, aiming to balance risk and growth [31][32]. Group 3: Market Dynamics and Future Outlook - The article notes a significant divergence in the performance and scale of pharmaceutical funds, with some funds experiencing a decline in assets despite strong returns, indicating a shift in investor behavior [19][23]. - The innovative drug sector is expected to enter a growth phase, driven by supportive policies, increased international transactions, and a projected surge in revenue for innovative drug companies by 2025 [35][36][41]. - The article concludes that the current favorable conditions for innovative drugs will likely sustain for the next two to three years, providing a platform for fund managers to implement their diverse investment strategies [43][44].

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Innovation Stock C fund, which has shown significant returns over various time frames [1] - As of August 19, 2025, the latest net value of the fund is 1.6905 yuan, reflecting a decrease of 1.73% [1] - The fund's one-month return is 7.28%, ranking 503 out of 1016 in its category; the six-month return is 60.19%, ranking 28 out of 977; and the year-to-date return is 70.36%, ranking 28 out of 967 [1] Group 2 - The top ten holdings of the China Europe Medical Innovation Stock C fund account for a total of 64.06%, with significant positions in companies such as Sanofi (8.99%), Kelun-Biotech (8.52%), and Kangfang Biotech (8.20%) [1] - The fund was established on February 28, 2019, and as of June 30, 2025, it has a total scale of 3.24 billion yuan [1] - The fund manager is Ms. Ge Lan, who has extensive experience in the investment management field, having joined China Europe Fund Management in October 2014 [2]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Innovation Stock C fund, which has shown a recent decline in net value but strong performance over the past six months and year-to-date [1] - The latest net value of the fund is 1.3561 yuan, reflecting a decrease of 0.74% [1] - The fund's one-month return is -1.63%, ranking 606 out of 673 in its category, while its six-month return is 43.34%, ranking 18 out of 659, and year-to-date return is 36.66%, ranking 22 out of 659 [1] Group 2 - The top ten stock holdings of the China Europe Medical Innovation Stock C fund account for a total of 75.62%, with significant positions in WuXi AppTec (10.35%), Kelun-Biotech (10.15%), WuXi Biologics (9.82%), and others [1] - The fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan [1] - The fund manager is Ms. Ge Lan, who has extensive experience in the investment management field, having worked with various funds since joining China Europe Fund Management in 2014 [2]

Core Viewpoint - The article discusses the performance and holdings of the China Europe Medical Innovation Stock C fund, highlighting its recent net value, returns, and top stock holdings [1]. Fund Performance - The latest net value of China Europe Medical Innovation Stock C is 1.2877 yuan, reflecting a decrease of 1.98% - The fund has achieved a return of 7.99% over the past month, ranking 75 out of 793 in its category - Over the last six months, the fund's return is 27.89%, ranking 30 out of 775 - Year-to-date, the fund has returned 29.77%, ranking 26 out of 775 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 75.62%, with the following key positions: - WuXi AppTec (10.35%) - Kelun-Biotech (10.15%) - WuXi Biologics (9.82%) - WuXi AppTec (9.60%) - CanSino Biologics (7.89%) - Hangzhou Tigermed Consulting (7.01%) - Hengrui Medicine (6.20%) - Kintor Pharmaceutical (5.87%) - Baillie Gifford (4.70%) - Tigermed (4.03%) [1]. Fund Background - China Europe Medical Innovation Stock C was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan - The fund manager is Ms. Ge Lan, who has extensive experience in the investment management field [1][2].

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 中欧医疗创新股票C股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 ...

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 来源：金融界 金融界2025年5月28日消息，中欧医疗创新股票C(006229) 最新净值1.2024元，下跌1.30%。该基金近1个 月收益率4.79%，同类排名69|801；近6个月收益率17.61%，同类排 ...

简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日)。现任中欧医疗健康混合型证券投资基金基金经理(自2016年9 月29日起至今),中欧明睿新起点混合型证券投资基金基金经理(自2018年7月12日起至今)、中欧阿尔法混 合型证券投资基金基金经理(2020年8月20日起至2023年9月28日)。 来源：金融界 金融界2025年4月25日消息，中欧医疗创新股票C(006229) 最新净值1.1626元，下跌1.43%。该基金近1个 月收益率3.72%，同类排名37|541；近3个月收益率20.12%，同类排 ...